The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.
This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2014.
There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.
Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.
Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.
The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all joint venture deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of joint venture dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of joint venture deals. The chapter includes numerous case studies to enable understanding of joint venture deals.
Chapter 4 provides a review of the leading Joint venture deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active Joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of Joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2014 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Joint venture deal.
The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2014. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.
Key benefits Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 provides the reader with the following key benefits: In-depth understanding of joint venture partnering deal trends since 2014 Analysis of the structure of joint venture agreements with numerous real life case studies Comprehensive listing of all joint venture deals since 2014, together with deal terms, value and press release Comprehensive access to actual joint venture contracts entered into by the world’s life science companies Insight into the terms included in a joint venture agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading life science companies worldwide.
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 includes: Trends in joint venture dealmaking in the biopharma industry since 2014 Analysis of joint venture deal structure Case studies of real-life joint venture deals Comprehensive listing of joint venture deals since 2014 Access to joint venture contract documents The leading joint venture deals by value since 2014 Most active joint venture dealmakers since 2014 The leading joint venture partnering resources
In Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 available deals and contracts are listed by: Company A-Z Headline value Therapeutic area Technology type
Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive access to available contract documents for joint venture deals. Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How do milestone align with clinical stage development phases? • How are sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
232 pages •
By BioInformant Worldwide, L.L.C.
• Dec 2020
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.” T-cells...
Gamma Secretase - Pipeline Review, H2 2020 Summary According to the recently published report ’Gamma Secretase - Pipeline Review, H2 2020’; Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining...
Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H2 2020 Summary Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses....
Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2020 Summary According to the recently published report ’Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2020’; Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)...
The vaccines market was valued at US$ 39,128.3 million in 2019 and is projected to reach US$ 64,538.4 million by 2027; it is expected to grow at a CAGR of 6.5% from 2020 to 2027.The major driving factors are rising prevalence of infectious diseases, growing focus on immunization programs, and increasing support for vaccine development are...
Type 2 Angiotensin II Receptor - Pipeline Review, H2 2020 Summary Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression...
Global Immunology Partnering 2014 to 2020 provides the full collection of Immunology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Immunology partnering deals Financial deal terms for headline, upfront and royalty by stage of development Immunology partnering...
Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Colorectal Cancer Diagnostic Tests pipeline products...
Global Hematology Partnering 2010 to 2020 provides the full collection of Hematology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010. Trends in Hematology partnering deals Financial deal terms for headline, upfront and royalty by stage of development Hematology partnering...
The Global Biomarker Partnering Terms and Agreements 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in biomarker partnering deals Biomarker...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.